HENDERSON, NV–(Marketwire – January 9, 2013) – Bergamo Acquisition Corp. (OTC: BGMO), a global investment holding company building a diversified portfolio of large and middle-market companies through strategic acquisitions and investments, today announced that it has entered into an investment agreement with National Wealth International Ltd., a privately held investment company.
National Wealth International Ltd. has provided Bergamo Acquisition’s wholly owned European subsidiary cashed-backed securities consisting of three separate tranches of 500 Million US Dollars issued through HSBC Bank, one of the world’s largest banking and financial services organizations. These funds will remain on deposit in accounts held by Bergamo Acquisition’s European subsidiary.
All profits generated from the use of the funds will be deposited in full to the bank of Bergamo’s European subsidiary company. These profits will be divided equally between National Wealth International Ltd. and the European subsidiary company of Bergamo Acquisition pursuant to the profit-sharing agreement between the parties.
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada.
In collaboration with Dr. Gordon Keller, one of the world’s leading stem cell researchers, we are developing engineered cell lines and enhancing protocols to control the differentiation of pluripotent stem cells into normal, mature, human liver cells for use in a novel liver cell-based bioassay system for predicting liver toxicity and metabolism issues in connection with our drug rescue activities. We refer to this novel human liver cell-based bioassay system as LiverSafe 3D™. We plan to complete development of LiverSafe 3D in early-2013.
Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.